SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : EARNINGS REPORTING - surprises, misses & more -- Ignore unavailable to you. Want to Upgrade?


To: 2MAR$ who wrote (547)4/13/2001 5:19:17 AM
From: 2MAR$  Respond to of 762
 
JNPR ( volatile, dip/run $51) Profits Rise , warns of flat 2001

NEW YORK (Reuters) - Networking equipment maker Juniper Networks Inc. (NasdaqNM:JNPR - news) on Thursday posted a seven-fold increase in first-quarter net income, but warned its 2001 earnings and revenues will fall below Wall Street forecasts due to the slowing U.S. economy and cutbacks in equipment spending by many service providers.

Juniper, which makes routers that speed traffic along communications networks, said net income, including amortization of goodwill and other items, jumped to $58.6 million, or 17 cents a share, from $8.1 million, or 2 cents a share, a year earlier.

Pro forma net income, which excludes those items, was $85.4 million, or 25 cents a share, compared with $10.5 million, or 3 cents a share, a year ago. The results were in line with Wall Street profit forecasts, which ranged from 21 to 25 cents a share, with a consensus forecast of 25 cents, according to research firm Thomson Financial/First Call.

``They performed extremely well across all metrics during the quarter,'' said Seth Spalding, an analyst with Epoch Partners.

First-quarter revenues increased 420 percent to $332.1 million, which was slightly lower than the $340 million expected by U.S. Bancorp Piper Jaffray.

Juniper's days sales outstanding (DSOs), a measure of how long it takes for a company to collect its bills from customers, were down slightly to 53 days in the quarter from 54 days in the prior quarter, which Spalding pointed to as a positive sign.

``If they'd scrambled to meet the quarter, DSOs would've gone up,'' he said. LACK OF BIG CUSTOMERS REDUCES VISIBILITY

But Sunnyvale, Calif.-based Juniper, whose core routers compete heavily with Cisco Systems Inc. (NasdaqNM:CSCO - news), cut its growth forecasts, saying it had limited visibility on near-term prospects due to the softening economy and spending cuts on network gear by telephone companies and other service providers.

During the first quarter, purchases by Juniper's key customer, WorldCom Inc. (NasdaqNM:WCOM - news), were ``significantly less'' of percentage of revenues than in previous quarters. Sales to WorldCom accounted for less than 10 percent of quarterly revenues ``for the first time,'' Juniper Chief Executive Scott Kriens told analysts on a conference call.

``Our customers have shortened buying horizons and are reluctant to purchase more than they need in the short-term,'' said Juniper Chief Financial Officer Marcel Gani.

Spalding said Juniper's lack of big customers was a cause for concern.

``It's hard to get visibility if the big guys aren't spending,'' he said.

Juniper said it expects second-quarter earnings of 25 cents a share, with revenues similar to those of the first quarter. Wall Street analysts had expected second-quarter earnings of 26 cents a share, according to First Call.

For the full year, Juniper said it expects earnings of 90 cents to $1 a share, on revenue growth of 85 to 100 percent.

Analysts had expected the company to post full-year earnings of $1 to $1.10 a share, with a consensus estimate of $1.05, according to First Call. Revenues were expected to be $1.598 billion, up 137 percent over last year's $673.5 million, First Call said. STOCK GAINS AS ANALYSTS RAISE RATINGS

Despite the warning, Juniper's stock gained more than 15 percent, to $50.38 at the close of Nasdaq trading after some analysts issued positive comments on the company.

CIBC World Markets said it raised Juniper to 'strong buy' from 'buy,' while traders said Merrill Lynch reiterated its long-term buy rating.

Shares of Juniper, which has been rumored as a potential merger partner of another networking infrastructure firm Redback Networks Inc. (NasdaqNM:RBAK - news), have fallen 62 percent over the past year, underperforming the Standard and Poor's 500 index by 53 percent. It is far off its 52-week high of $244.50.

Juniper is just one of several equipment makers hurt by a lagging economy and slower capital spending. Others include Nortel Networks Corp. (NYSE:NT - news) (Toronto:NT.TO - news), Motorola Inc. (NYSE:MOT - news), ADC Telecommunications Inc. (NasdaqNM:ADCT - news) and Cisco.

Juniper said it remains confident about demand for its high-speed routing products from telecommunication carriers, and will continue to hire new workers, though at a slower pace than in the past.

``This market is not going away...,'' Kriens said, ``but we must also operate within the reality that there's no immunity to short-term fluctuations.''



To: 2MAR$ who wrote (547)4/13/2001 5:35:17 AM
From: 2MAR$  Read Replies (1) | Respond to of 762
 
BGEN ($62..+2) DNA ($50 up 2) , biotech stocks on the rise

By Ted Griffith, CBS.MarketWatch.com
Last Update: 5:27 PM ET Apr 12, 2001




NEW YORK (CBS.MW) -- Biotechnology stocks moved sharply higher Thursday, with stock of Biogen leading the ascent after the company reported strong sales growth of its multiple sclerosis drug.



The Amex Biotechnology Index (BTK: news, msgs, alerts) added 6.7 percent and the Nasdaq Biotechnology Index (NBI: news, msgs, alerts) increased 6.1 percent.

Shares of Biogen (BGEN: news, msgs, alerts) gained $3.67, or 6.3 percent, to $61.78. Biogen reported before the opening of trading that first-quarter sales of its multiple sclerosis drug, Avonex, surged 26 percent to a record $220 million. Biogen's profit, before special gains and taxes, rose 3 percent to $86.6 million.

In a note to clients, analyst Eric Schmidt at SG Cowen said first-quarter Avonex sales topped his expectations by 7 million and he said Avonex sales for the year could exceed his estimate of $937 million.

Through 2003, Schmidt said he expects Avonex sales growth in the "mid-teens" fueled partly by "earlier diagnoses of multiple sclerosis."

Shares of two other large profitable biotechnology companies, Amgen and Genzyme, also gained ground. Shares of Amgen (AMGN: news, msgs, alerts) rose $2.27 to $54.14 while Genzyme (GENZ: news, msgs, alerts) stock increased $4.55 to $101.23.

After the close of regular trading, Genentech (DNA: news, msgs, alerts) said first-quarter net income increased 20 percent to $91.2 million, or 17 cents per share, compared to $76 million, or 14 cents per share, in the year-ago period. Genentech got a boost from strong sales of the cancer drug, Rituxan, which rose 102 percent to $172.1 million from $85.1 million in last year's first quarter.

Stock of Genentech edged up 40 cents to $45.65 in regular trading

Ted Griffith is a reporter for CBS.MarketWatch.com